Abstract
Few studies have examined probiotic prophylaxis in patients with acute pancreatitis, and those that have been performed have yielded conflicting results. In this Practice Point commentary, I discuss the findings and limitations of a study by Besselink et al., which assessed the effects of a multispecies probiotic preparation in patients with predicted severe acute pancreatitis. The preparation did not reduce infectious complications, and increased mortality. However, it is necessary to remember that large genetic and functional differences exist between various strains of bacteria and that only a few lactic acid bacteria (LAB) have demonstrated an ability to significantly reduce inflammation, control infection and provide health benefits to humans. Choice of LAB and dose of LAB is critical for outcome. Extensive preclinical studies are essential before recommendations for new cocktails of probiotics can be introduced in clinical practice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Frossard JL et al. (2008) Acute pancreatitis. Lancet 371: 143–152
Oláh A et al. (2002) Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 89: 1103–1107
Oláh A et al. (2007) Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepatogastroenterology 54: 590–594
Besselink MG et al. (2008) Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371: 651–659
Sand J and Nordback I (2008) Probiotics in severe acute pancreatitis. Lancet 371: 634–635
Bengmark S : Bio-ecological control of chronic liver disease and encephalopathy. Metab Brain Dis, in press
Bengmark S (2006) Bioecologic control of inflammation and infection in critical illness. Anesthesiol Clin 24: 299–323
Author information
Authors and Affiliations
Ethics declarations
Competing interests
S Bengmark is a Consultant for Medipharm AB.
Rights and permissions
About this article
Cite this article
Bengmark, S. Is probiotic prophylaxis worthwhile in patients with predicted severe acute pancreatitis?. Nat Rev Gastroenterol Hepatol 5, 602–603 (2008). https://doi.org/10.1038/ncpgasthep1260
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep1260